Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
WINGER DENNIS L
  2. Issuer Name and Ticker or Trading Symbol
APPLIED BIOSYSTEMS INC. [ABI]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Senior Vice President and CFO
(Last)
(First)
(Middle)
APPLIED BIOSYSTEMS INC., 301 MERRITT 7
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2008
(Street)

NORWALK, CT 06851-1070
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Applied Biosystems Group Common Stock 11/17/2008   M   85,860 A $ 25.575 154,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   20,000 A $ 25 174,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   20,000 A $ 25 194,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   85,000 A $ 20.85 279,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   20,000 A $ 15.54 299,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   20,000 A $ 15.54 319,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   30,000 A $ 15.54 349,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   68,000 A $ 20.185 417,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   M   90,000 A $ 21.475 507,143.2555 D  
Applied Biosystems Group Common Stock 11/17/2008   S   375,423 D $ 29.2019 (1) 131,720.2555 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Applied Biosystems Group Employee Stock Options-Right to Buy $ 25.575 11/17/2008   M     85,860   (2) 03/26/2011 Applied Biosystems Group Common Stock 85,860 $ 0 4,140 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 25 11/17/2008   M     20,000 08/16/2004 08/16/2011 Applied Biosystems Group Common Stock 20,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 25 11/17/2008   M     20,000   (3) 08/16/2011 Applied Biosystems Group Common Stock 20,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 20.85 11/17/2008   M     85,000   (4) 04/08/2012 Applied Biosystems Group Common Stock 85,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 15.54 11/17/2008   M     20,000   (5) 03/24/2013 Applied Biosystems Group Common Stock 20,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 15.54 11/17/2008   M     20,000   (6) 03/24/2013 Applied Biosystems Group Common Stock 20,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 15.54 11/17/2008   M     30,000   (7) 03/24/2013 Applied Biosystems Group Common Stock 30,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 20.185 11/17/2008   M     68,000   (8) 06/17/2014 Applied Biosystems Group Common Stock 68,000 $ 0 0 D  
Applied Biosystems Group Employee Stock Options-Right to Buy $ 21.475 11/17/2008   M     90,000   (9) 06/02/2015 Applied Biosystems Group Common Stock 90,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
WINGER DENNIS L
APPLIED BIOSYSTEMS INC.
301 MERRITT 7
NORWALK, CT 06851-1070
      Senior Vice President and CFO  

Signatures

 /s/ Thomas P. Livingston, Attorney-In-Fact for Dennis L. Winger   11/19/2008
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The price reported is the weighted average sale price in open market transactions at prices ranging from $29.35 to $29.05. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
(2) These options originally became exercisable in four equal annual installments, commencing March 26, 2002. Effective January 20, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect for some of the shares until March 26, 2005.
(3) These options originally became exercisable on or after the earlier of (a) August 16, 2006 or (b) two years after certain stock price targets were attained. The vesting of these options was accelerated effective June 2, 2005. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that was to remain in effect until the earlier of the original vesting date of those options or termination of the reporting person's employment with the issuer.
(4) These options originally became exercisable in four equal annual installments, commencing April 8, 2003. Effective January 20, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect for some of the shares until April 8, 2006.
(5) As originally granted, these options would have become exercisable on March 24, 2006. Effective June 2, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect until March 24, 2006.
(6) These options originally became exercisable on or after the earlier of (a) March 24, 2008 or (b) two years after certain stock price targets were attained. The vesting of these options was accelerated effective June 2, 2005. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that was to remain in effect until the earlier of the original vesting date of those options or termination of the reporting person's employment with the issuer.
(7) These options originally became exercisable in four equal annual installments, commencing March 24, 2004. Effective January 20, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect for some of the shares until March 24, 2007.
(8) These options originally became exercisable in four equal annual installments, commencing June 17, 2005. Effective January 20, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect for some of the shares until June 17, 2008.
(9) These options were fully vested and exercisable as of June 2, 2005, the grant date. However, shares acquired upon the exercise of these options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition). The transfer restriction was scheduled to lapse on 25% of the shares covered by the grant on each of the first four anniversaries of the grant date. Also, the transfer restriction would have lapsed in full upon termination of employment for any reason. However, all remaining restrictions were terminated on November 12, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.